Description: CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
Home Page: www.cytomx.com
CTMX Technical Analysis
151 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 515 3185
Officers
| Name | Title |
|---|---|
| Dr. Sean A. McCarthy D.Phil., DPHIL | Chairman & CEO |
| Mr. Lloyd A. Rowland Jr., J.D. | Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. |
| Mr. Christopher W. Ogden | Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer |
| Dr. Chau Cheng M.B.A., Ph.D. | VP of Investor Relations & Corp. Communications |
| Ms. Danielle Olander-Moghadassian | Sr. VP & Chief HR Officer |
| Ms. Leslie Robbins | Sr. VP of Intellectual Property |
| Dr. Marcia P. Belvin Ph.D. | Sr. VP & Head of Research |
| Mr. Jeffrey Landau B.S., M.B.A. | Sr. VP, Head of Strategy & Chief Bus. Officer |
| Dr. Jamie Moore Ph.D. | Sr. VP & Head of Protein and Process Sciences and Manufacturing |
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Exec. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.8062 |
| Price-to-Sales TTM: | 1.4467 |
| IPO Date: | 2015-10-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 174 |